225 related articles for article (PubMed ID: 27179249)
21. Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors.
Laverman P; Béhé M; Oyen WJ; Willems PH; Corstens FH; Behr TM; Boerman OC
Bioconjug Chem; 2004; 15(3):561-8. PubMed ID: 15149184
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and evaluation of a
Radford L; Gallazzi F; Watkinson L; Carmack T; Berendzen A; Lewis MR; Jurisson SS; Papagiannopoulou D; Hennkens HM
Nucl Med Biol; 2017 Apr; 47():4-9. PubMed ID: 28043006
[TBL] [Abstract][Full Text] [Related]
23. Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy.
Jung KH; Lee KH; Paik JY; Ko BH; Bae JS; Lee BC; Sung HJ; Kim DH; Choe YS; Chi DY
J Nucl Med; 2006 Dec; 47(12):2000-7. PubMed ID: 17138743
[TBL] [Abstract][Full Text] [Related]
24. Non-glycosylated tandem repeats of MUC1 facilitate attachment of breast tumor cells to normal human lung tissue and immobilized extracellular matrix proteins (ECM) in vitro: potential role in metastasis.
Ciborowski P; Finn OJ
Clin Exp Metastasis; 2002; 19(4):339-45. PubMed ID: 12090474
[TBL] [Abstract][Full Text] [Related]
25. A new radiopharmaceutical compound (131I-PR81) for radioimmunotherapy of breast cancer: labeling of antibody and its quality control.
Mohammadnejad J; Rasaee MJ; Babaei MH; Paknejad M; Zahir MH; Salouti M; Rajabi AB; Mazidi M
Hum Antibodies; 2010; 19(4):79-88. PubMed ID: 21178279
[TBL] [Abstract][Full Text] [Related]
26. Preparation, Radiolabeling with
Okarvi SM
Pharmaceuticals (Basel); 2023 Nov; 16(11):. PubMed ID: 38004416
[TBL] [Abstract][Full Text] [Related]
27. Molecular imaging of MDM2 messenger RNA with 99mTc-labeled antisense oligonucleotides in experimental human breast cancer xenografts.
Fu P; Shen B; Zhao C; Tian G
J Nucl Med; 2010 Nov; 51(11):1805-12. PubMed ID: 20956468
[TBL] [Abstract][Full Text] [Related]
28. Effects of the antifolates pemetrexed and CB3717 on the tissue distribution of (99m)Tc-EC20 in xenografted and syngeneic tumor-bearing mice.
Müller C; Reddy JA; Leamon CP; Schibli R
Mol Pharm; 2010 Apr; 7(2):597-604. PubMed ID: 20199053
[TBL] [Abstract][Full Text] [Related]
29.
Ahmadpour S; Noaparast Z; Abedi SM; Hosseinimehr SJ
Anticancer Agents Med Chem; 2018; 18(9):1295-1302. PubMed ID: 29521248
[TBL] [Abstract][Full Text] [Related]
30. Novel breast-tumor-associated MUC1-derived peptides: characterization in Db-/- x beta2 microglobulin (beta2m) null mice transgenic for a chimeric HLA-A2.1/Db-beta2 microglobulin single chain.
Carmon L; El-Shami KM; Paz A; Pascolo S; Tzehoval E; Tirosh B; Koren R; Feldman M; Fridkin M; Lemonnier FA; Eisenbach L
Int J Cancer; 2000 Feb; 85(3):391-7. PubMed ID: 10652432
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and in vitro and in vivo evaluation of an (18)F-labeled neuropeptide Y analogue for imaging of breast cancer by PET.
Hofmann S; Maschauer S; Kuwert T; Beck-Sickinger AG; Prante O
Mol Pharm; 2015 Apr; 12(4):1121-30. PubMed ID: 25748228
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent.
Okarvi SM; al-Jammaz I
Anticancer Res; 2003; 23(3B):2745-50. PubMed ID: 12894569
[TBL] [Abstract][Full Text] [Related]
33. [99mTc]HYNIC-RGD for imaging integrin alphavbeta3 expression.
Decristoforo C; Faintuch-Linkowski B; Rey A; von Guggenberg E; Rupprich M; Hernandez-Gonzales I; Rodrigo T; Haubner R
Nucl Med Biol; 2006 Nov; 33(8):945-52. PubMed ID: 17127166
[TBL] [Abstract][Full Text] [Related]
34. [In vivo imaging of breast tumors by a
Kang L; Huo Y; Wang RF; Zhang CL; Yan P; Xu XJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2018 Apr; 50(2):326-330. PubMed ID: 29643534
[TBL] [Abstract][Full Text] [Related]
35. Comparison of biological properties of
Zhao ZQ; Yang Y; Fang W; Liu S
Nucl Med Biol; 2016 Nov; 43(11):661-669. PubMed ID: 27556955
[TBL] [Abstract][Full Text] [Related]
36. Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma.
Henderikx P; Kandilogiannaki M; Petrarca C; von Mensdorff-Pouilly S; Hilgers JH; Krambovitis E; Arends JW; Hoogenboom HR
Cancer Res; 1998 Oct; 58(19):4324-32. PubMed ID: 9766660
[TBL] [Abstract][Full Text] [Related]
37. Synthesis, radiolabeling and in vitro and in vivo characterization of a technetium-99m-labeled alpha-M2 peptide as a tumor imaging agent.
Okarvi SM
J Pept Res; 2004 Jun; 63(6):460-8. PubMed ID: 15175018
[TBL] [Abstract][Full Text] [Related]
38. PEGylation of (99m)Tc-labeled bombesin analogues improves their pharmacokinetic properties.
Däpp S; García Garayoa E; Maes V; Brans L; Tourwé DA; Müller C; Schibli R
Nucl Med Biol; 2011 Oct; 38(7):997-1009. PubMed ID: 21982571
[TBL] [Abstract][Full Text] [Related]
39. Anti-MUC1 aptamers: radiolabelling with (99m)Tc and biodistribution in MCF-7 tumour-bearing mice.
Pieve CD; Perkins AC; Missailidis S
Nucl Med Biol; 2009 Aug; 36(6):703-10. PubMed ID: 19647177
[TBL] [Abstract][Full Text] [Related]
40. Synthesis, in vitro pharmacologic characterization, and preclinical evaluation of N-[2-(1'-piperidinyl)ethyl]-3-[125I]iodo-4-methoxybenzamide (P[125I]MBA) for imaging breast cancer.
John CS; Bowen WD; Fisher SJ; Lim BB; Geyer BC; Vilner BJ; Wahl RL
Nucl Med Biol; 1999 May; 26(4):377-82. PubMed ID: 10382840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
